Emmaus Life Sciences, Inc. (EMMA)
USD 0.02
(-12.28%)
USD 0.02
(-12.28%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 82.93 Million USD | 0.75% |
| 2022 | 82.31 Million USD | 5.28% |
| 2021 | 78.18 Million USD | 20.85% |
| 2020 | 64.69 Million USD | -8.25% |
| 2019 | 70.5 Million USD | 3680.04% |
| 2018 | 1.86 Million USD | 20.44% |
| 2017 | 1.54 Million USD | -1.77% |
| 2016 | 1.57 Million USD | -70.82% |
| 2015 | 5.4 Million USD | 74.44% |
| 2014 | 3.09 Million USD | -13.04% |
| 2013 | 3.56 Million USD | -73.01% |
| 2012 | 13.2 Million USD | 11.95% |
| 2011 | 11.79 Million USD | 165.47% |
| 2010 | 4.44 Million USD | 95.59% |
| 2009 | 2.27 Million USD | 43.68% |
| 2008 | 1.58 Million USD | 139.74% |
| 2007 | 659.3 Thousand USD | 100.09% |
| 2006 | 329.5 Thousand USD | 5.29% |
| 2005 | 312.94 Thousand USD | 7.05% |
| 2004 | 292.32 Thousand USD | 981.83% |
| 2003 | 27.02 Thousand USD | 59.62% |
| 2002 | 16.92 Thousand USD | 13.73% |
| 2001 | 14.88 Thousand USD | 134.63% |
| 2000 | 6344.00 USD | -36.56% |
| 1999 | 10 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 82.95 Million USD | -0.28% |
| 2024 Q1 | 83.18 Million USD | 0.3% |
| 2023 Q3 | 83.78 Million USD | -1.8% |
| 2023 FY | 82.93 Million USD | 0.75% |
| 2023 Q1 | 84.89 Million USD | 3.14% |
| 2023 Q2 | 85.32 Million USD | 0.5% |
| 2023 Q4 | 82.93 Million USD | -1.01% |
| 2022 FY | 82.31 Million USD | 5.28% |
| 2022 Q2 | 80.62 Million USD | 9.26% |
| 2022 Q1 | 73.79 Million USD | -5.62% |
| 2022 Q3 | 79.79 Million USD | -1.03% |
| 2022 Q4 | 82.31 Million USD | 3.17% |
| 2021 Q2 | 72.65 Million USD | -3.0% |
| 2021 FY | 78.18 Million USD | 20.85% |
| 2021 Q4 | 78.18 Million USD | 4.03% |
| 2021 Q3 | 75.15 Million USD | 3.45% |
| 2021 Q1 | 74.89 Million USD | 15.77% |
| 2020 Q2 | 70.26 Million USD | -0.64% |
| 2020 FY | 64.69 Million USD | -8.25% |
| 2020 Q1 | 70.72 Million USD | 0.3% |
| 2020 Q4 | 64.69 Million USD | -2.44% |
| 2020 Q3 | 66.3 Million USD | -5.64% |
| 2019 FY | 70.5 Million USD | 3680.04% |
| 2019 Q2 | 2.66 Million USD | 1.35% |
| 2019 Q3 | 74.73 Million USD | 2704.73% |
| 2019 Q4 | 70.5 Million USD | -5.65% |
| 2019 Q1 | 2.62 Million USD | 14.25% |
| 2018 Q4 | 2.3 Million USD | 23.36% |
| 2018 Q3 | 1.86 Million USD | -8.58% |
| 2018 Q2 | 2.04 Million USD | -24.3% |
| 2018 Q1 | 2.69 Million USD | 11.67% |
| 2018 FY | 1.86 Million USD | 20.44% |
| 2017 Q3 | 1.54 Million USD | -28.54% |
| 2017 FY | 1.54 Million USD | -1.77% |
| 2017 Q4 | 2.41 Million USD | 55.85% |
| 2017 Q2 | 2.16 Million USD | 13.86% |
| 2017 Q1 | 1.9 Million USD | 11.74% |
| 2016 Q4 | 1.7 Million USD | 8.04% |
| 2016 Q1 | 7.27 Million USD | -4.02% |
| 2016 FY | 1.57 Million USD | -70.82% |
| 2016 Q2 | 8.17 Million USD | 12.43% |
| 2016 Q3 | 1.57 Million USD | -80.72% |
| 2015 Q3 | 5.4 Million USD | 37.99% |
| 2015 FY | 5.4 Million USD | 74.44% |
| 2015 Q4 | 7.57 Million USD | 40.23% |
| 2015 Q2 | 3.91 Million USD | 8.71% |
| 2015 Q1 | 3.6 Million USD | 17.76% |
| 2014 Q2 | 1.55 Million USD | 8.31% |
| 2014 Q1 | 1.43 Million USD | -9.55% |
| 2014 Q4 | 3.05 Million USD | -1.24% |
| 2014 FY | 3.09 Million USD | -13.04% |
| 2014 Q3 | 3.09 Million USD | 99.75% |
| 2013 FY | 3.56 Million USD | -73.01% |
| 2013 Q1 | 12.45 Million USD | -14.65% |
| 2013 Q4 | 1.58 Million USD | -55.56% |
| 2013 Q3 | 3.56 Million USD | -70.18% |
| 2013 Q2 | 11.94 Million USD | -4.11% |
| 2012 FY | 13.2 Million USD | 11.95% |
| 2012 Q4 | 14.59 Million USD | 10.56% |
| 2012 Q3 | 13.2 Million USD | -27.09% |
| 2012 Q2 | 18.1 Million USD | -19.82% |
| 2012 Q1 | 22.58 Million USD | 58.15% |
| 2011 Q3 | 11.79 Million USD | 12.64% |
| 2011 Q1 | 11.46 Million USD | 143.14% |
| 2011 FY | 11.79 Million USD | 165.47% |
| 2011 Q2 | 10.46 Million USD | -8.73% |
| 2011 Q4 | 14.27 Million USD | 21.09% |
| 2010 Q2 | 2.01 Million USD | 8.5% |
| 2010 FY | 4.44 Million USD | 95.59% |
| 2010 Q4 | 4.71 Million USD | 6.2% |
| 2010 Q1 | 1.85 Million USD | -3.51% |
| 2010 Q3 | 4.44 Million USD | 120.12% |
| 2009 Q1 | 2.56 Million USD | 48.15% |
| 2009 FY | 2.27 Million USD | 43.68% |
| 2009 Q4 | 1.92 Million USD | -15.13% |
| 2009 Q2 | 3.12 Million USD | 21.52% |
| 2009 Q3 | 2.27 Million USD | -27.27% |
| 2008 Q2 | 1.45 Million USD | 31.14% |
| 2008 Q1 | 1.11 Million USD | 85.44% |
| 2008 FY | 1.58 Million USD | 139.74% |
| 2008 Q4 | 1.73 Million USD | 9.74% |
| 2008 Q3 | 1.58 Million USD | 8.54% |
| 2007 Q2 | 586.2 Thousand USD | -79.91% |
| 2007 Q1 | 2.91 Million USD | 785.56% |
| 2007 FY | 659.3 Thousand USD | 100.09% |
| 2007 Q4 | 598.8 Thousand USD | -9.27% |
| 2007 Q3 | 660 Thousand USD | 12.59% |
| 2006 Q1 | 322.49 Thousand USD | 3.05% |
| 2006 Q3 | 276.95 Thousand USD | -16.68% |
| 2006 Q4 | 329.5 Thousand USD | 18.98% |
| 2006 FY | 329.5 Thousand USD | 5.29% |
| 2006 Q2 | 332.38 Thousand USD | 3.07% |
| 2005 Q4 | 312.94 Thousand USD | -4.02% |
| 2005 Q1 | 307.78 Thousand USD | 5.29% |
| 2005 Q2 | 314.64 Thousand USD | 2.23% |
| 2005 FY | 312.94 Thousand USD | 7.05% |
| 2005 Q3 | 326.03 Thousand USD | 3.62% |
| 2004 FY | 292.32 Thousand USD | 981.83% |
| 2004 Q4 | 292.32 Thousand USD | 59.33% |
| 2004 Q2 | 667.42 Thousand USD | 2178.9% |
| 2004 Q1 | 29.28 Thousand USD | 8.39% |
| 2004 Q3 | 183.47 Thousand USD | -72.51% |
| 2003 Q1 | 20.22 Thousand USD | 19.45% |
| 2003 Q2 | 22.1 Thousand USD | 9.3% |
| 2003 Q3 | 22.46 Thousand USD | 1.66% |
| 2003 Q4 | 27.02 Thousand USD | 20.26% |
| 2003 FY | 27.02 Thousand USD | 59.62% |
| 2002 Q3 | 14.89 Thousand USD | -22.69% |
| 2002 Q4 | 16.92 Thousand USD | 13.62% |
| 2002 Q2 | 19.27 Thousand USD | 6.62% |
| 2002 Q1 | 18.07 Thousand USD | 21.44% |
| 2002 FY | 16.92 Thousand USD | 13.73% |
| 2001 Q1 | 9635.00 USD | -3.65% |
| 2001 Q2 | 10.39 Thousand USD | 7.92% |
| 2001 Q4 | 14.88 Thousand USD | 55.38% |
| 2001 FY | 14.88 Thousand USD | 134.63% |
| 2001 Q3 | 9580.00 USD | -7.87% |
| 2000 FY | 6344.00 USD | -36.56% |
| 2000 Q1 | - USD | -100.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | 10 Thousand USD | 0.0% |
| 1999 Q2 | 130 Thousand USD | 0.0% |
| 1999 Q3 | 130 Thousand USD | 0.0% |
| 1999 Q4 | 10 Thousand USD | -92.31% |
| 1999 FY | 10 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -302218.376% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -776.143% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -14.439% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -10154.156% |
| Rebus Holdings, Inc. | 5.24 Million USD | -1482.125% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -40.534% |
| Qrons Inc. | 1.48 Million USD | -5470.919% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -6663.507% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -10.698% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -185453.517% |
| Skye Bioscience, Inc. | 14.07 Million USD | -489.352% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -55.586% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -765.527% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -19572.983% |
| SQZ Biotechnologies Company | 50.03 Million USD | -65.741% |
| Intellipharmaceutics International Inc. | 12 Million USD | -590.62% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -2053.359% |
| Mesoblast Limited | 188.44 Million USD | 55.99% |
| Marizyme, Inc. | 26.67 Million USD | -210.901% |
| Genus plc | 485 Million USD | 82.9% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -1319.483% |
| Pharming Group N.V. | 244.07 Million USD | 66.02% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -4025.853% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -3195.874% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -2082.5% |
| ContraFect Corporation | 32.53 Million USD | -154.941% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -4085.871% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -2066.735% |
| IMV Inc. | 37.93 Million USD | -118.637% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -604.14% |
| MultiCell Technologies, Inc. | 1617.67 USD | -5126718.201% |
| ONE Bio Corp. | 27.49 Million USD | -201.628% |
| Accustem Sciences Inc. | 1.07 Million USD | -7584.581% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -7.128% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -3821.149% |
| Q BioMed Inc. | 8.13 Million USD | -919.742% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -1511.629% |
| Biomind Labs Inc. | 1.49 Million USD | -5434.121% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 30.144% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -817.2% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -350.65% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -5684.033% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -58265.882% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -41137.395% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -1343.397% |
| GB Sciences, Inc. | 5.41 Million USD | -1430.856% |
| Alpha Cognition Inc. | 7.16 Million USD | -1057.538% |
| HST Global, Inc. | 593.59 Thousand USD | -13871.694% |
| CSL Limited | 18.62 Billion USD | 99.555% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -6486.361% |
| Halberd Corporation | 728.71 Thousand USD | -11280.93% |
| Enzolytics Inc. | 365.26 Million USD | 77.295% |
| Agentix Corp. | 2.51 Million USD | -3203.453% |
| Resverlogix Corp. | 67.39 Million USD | -23.056% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -9788.141% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 81.361% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -4738.681% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -235.145% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -596.751% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -2162.791% |
| AVAX Technologies, Inc. | 3.99 Million USD | -1976.622% |
| Zenith Capital Corp. | 27.56 Thousand USD | -300727.016% |
| Genscript Biotech Corporation | 1.32 Billion USD | 93.745% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -34651.146% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -2120.895% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -12081.383% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -2958.48% |
| Kadimastem Ltd | 3.5 Million USD | -2266.281% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -123814.895% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -64.999% |
| BioStem Technologies, Inc. | 15.9 Million USD | -421.451% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -17747.036% |
| LadRx Corporation | 2.2 Million USD | -3668.868% |
| Cell Source, Inc. | 15.8 Million USD | -424.682% |
| Regen BioPharma, Inc. | 5.45 Million USD | -1419.62% |
| Regen BioPharma, Inc. | 5.45 Million USD | -1419.62% |
| NovAccess Global Inc. | 7.86 Million USD | -955.054% |
| Affymax, Inc. | 8.87 Million USD | -834.9% |
| Itoco Inc. | 1.65 Million USD | -4916.783% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -3942.524% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -1271.053% |
| Mobile Lads Corp. | 1.31 Million USD | -6214.061% |
| CytoDyn Inc. | 127.89 Million USD | 35.153% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -198313.838% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -5194.702% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -650.863% |
| SYBLEU INC | 681.41 Thousand USD | -12071.033% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -1259.166% |
| International Stem Cell Corporation | 5.27 Million USD | -1471.632% |
| Bioxytran, Inc. | 3.24 Million USD | -2452.239% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -13152.446% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -1696.248% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -102.3% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -272.49% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -3994.773% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -1413.965% |
| Neutra Corp. | 973.52 Thousand USD | -8419.007% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -185.835% |
| PureTech Health plc | 125.58 Million USD | 33.96% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -2107.406% |
| IXICO plc | 1.9 Million USD | -4264.329% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -303.989% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 19.733% |
| CSL Limited | 18.62 Billion USD | 99.555% |
| Cellectis S.A. | 249.36 Million USD | 66.742% |